JP2018519366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519366A5 JP2018519366A5 JP2018518786A JP2018518786A JP2018519366A5 JP 2018519366 A5 JP2018519366 A5 JP 2018519366A5 JP 2018518786 A JP2018518786 A JP 2018518786A JP 2018518786 A JP2018518786 A JP 2018518786A JP 2018519366 A5 JP2018519366 A5 JP 2018519366A5
- Authority
- JP
- Japan
- Prior art keywords
- muscular atrophy
- drug
- condition causing
- physical condition
- fgf19 polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305990.2 | 2015-06-25 | ||
| EP15305990.2A EP3108893A1 (en) | 2015-06-25 | 2015-06-25 | Novel therapeutic use of fgf19 |
| PCT/EP2016/064671 WO2016207354A1 (en) | 2015-06-25 | 2016-06-24 | Novel therapeutic use of fgf19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519366A JP2018519366A (ja) | 2018-07-19 |
| JP2018519366A5 true JP2018519366A5 (enExample) | 2019-08-22 |
| JP6761929B2 JP6761929B2 (ja) | 2020-09-30 |
Family
ID=53498933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518786A Active JP6761929B2 (ja) | 2015-06-25 | 2016-06-24 | Ｆｇｆ１９の新規な治療用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10695403B2 (enExample) |
| EP (2) | EP3108893A1 (enExample) |
| JP (1) | JP6761929B2 (enExample) |
| CA (1) | CA2997652A1 (enExample) |
| WO (1) | WO2016207354A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| MX383664B (es) | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| SG10202104575WA (en) * | 2016-11-04 | 2021-06-29 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| JP2020100591A (ja) * | 2018-12-21 | 2020-07-02 | 味の素株式会社 | 筋質向上剤 |
| CN112057606B (zh) * | 2020-09-14 | 2023-09-19 | 上海市儿童医院 | Fgf19在治疗和/或预防脓毒症诱发的器官损伤的药物中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040126852A1 (en) * | 1997-11-25 | 2004-07-01 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| EP1032668B1 (en) * | 1997-11-25 | 2008-05-28 | Genentech, Inc. | Fibroblast growth factor-19 |
| CA2644046A1 (en) * | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Metabolic regulators and uses thereof |
| CA2777717C (en) * | 2009-10-15 | 2021-05-25 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
| US8951966B2 (en) * | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
-
2015
- 2015-06-25 EP EP15305990.2A patent/EP3108893A1/en not_active Withdrawn
-
2016
- 2016-06-24 US US15/739,238 patent/US10695403B2/en active Active
- 2016-06-24 CA CA2997652A patent/CA2997652A1/en not_active Abandoned
- 2016-06-24 WO PCT/EP2016/064671 patent/WO2016207354A1/en not_active Ceased
- 2016-06-24 JP JP2018518786A patent/JP6761929B2/ja active Active
- 2016-06-24 EP EP16733413.5A patent/EP3313430B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012041342A5 (enExample) | ||
| JP2011225596A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2007526248A5 (enExample) | ||
| FI3721882T3 (fi) | Aineenvaihduntahäiriöiden hoito hevoseläimissä | |
| HRP20201353T1 (hr) | Agonisti glukagonskog receptora | |
| NZ603200A (en) | Peptides and their use | |
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| JP2016509011A5 (enExample) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2014530220A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| JP2011241213A5 (enExample) | ||
| WO2015105981A3 (en) | Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment | |
| MX2023010328A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| JP2009544585A5 (enExample) | ||
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP2013510169A5 (enExample) | ||
| EA200600782A1 (ru) | Терапевтические применения вариантов хемокинов | |
| JP2009500045A5 (enExample) | ||
| EP4470611A3 (en) | Levodopa and carbidopa intestinal gel and methods of use | |
| UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью |